drugset / Trial / NCT03962725

Avoiding Neuromuscular Blockers to Reduce Complications

NCT03962725

Phase 4 Terminated 3 enrolled Beth Israel Deaconess Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this study to evaluate whether eliminating the use of non-depolarizing neuromuscular blocking agents (NMBA) for maintenance of general anesthesia reduces postoperative pulmonary complications in higher risk patients.

Timeline

Start
2019-08-07
Primary completion
2022-12-19
Completion
2022-12-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rocuronium Other / unclassified 0.6 mg/kg
Comparator Rocuronium Other / unclassified 1 mg/kg
Background Dexmedetomidine Other / unclassified
Background Ketamine Small molecule
Background Propofol Small molecule